A 48-year-old man with spinal epidural lipomatosis and critical stenosis achieved near-complete reversal of spinal fat accumulation and resolution of stenosis after losing 59 kg on semaglutide over one year, avoiding surgery.
59.2 kg weight loss, surgery avoidedA man with critical spinal stenosis from fat accumulation achieved near-complete reversal on semaglutide over one year — the first documented case of non-surgical SEL resolution
What the researchers found
A 48-year-old man with morbid obesity (153 kg), extensive spinal epidural lipomatosis, and critical lumbar stenosis underwent a non-surgical treatment strategy:
- Semaglutide initiated for GLP-1-mediated weight loss
- Medical cannabis for non-opioid pain control
- Over 1 year follow-up: weight decreased from 153 kg to 93.8 kg (59.2 kg loss)
- MRI demonstrated near-complete regression of epidural fat
- Resolution of spinal stenosis
- Major improvement in pain and mobility
- Patient remained neurologically intact
- Surgery was successfully avoided
- Reported as the first documented case of SEL reversal through medical weight loss alone
Why it matters
Spinal epidural lipomatosis typically requires surgical decompression, which carries risks and recovery time. This case demonstrates that GLP-1-mediated weight loss can completely reverse this condition, potentially offering a non-surgical alternative. As semaglutide is already widely available, this approach could change the management algorithm for obesity-related spinal conditions.
How the study worked
This is a single-patient case report documenting a non-surgical treatment approach for spinal epidural lipomatosis. The patient received semaglutide for weight loss and medical cannabis for pain management. Clinical outcomes were assessed through weight monitoring, pain and mobility evaluations, neurological examinations, and serial MRI imaging over one year of follow-up.
What this study cannot tell us
This is a single case report and cannot establish generalizability. The contribution of semaglutide versus weight loss alone versus medical cannabis to the improvement cannot be separated. The long-term durability of the fat regression is unknown, particularly if weight is regained after stopping semaglutide. Not all patients with SEL may respond similarly, especially those whose condition is caused by corticosteroids rather than obesity.
How to read the evidence
This is a single case report — the lowest level of clinical evidence. While the result is dramatic and well-documented with MRI, it cannot be generalized without larger studies.
When this study was published
Published in 2026, this is a very recent case report reflecting the expanding clinical applications of GLP-1-mediated weight loss.
The bigger picture
This case illustrates how GLP-1-mediated weight loss can reverse conditions previously thought to require surgery. As obesity-related complications expand beyond diabetes and cardiovascular disease, cases like this highlight the broader surgical-avoidance potential of substantial weight loss achieved with GLP-1 drugs. Similar reports have emerged for obesity-related joint conditions, sleep apnea, and other mechanical complications of excess weight.
Questions still open
- Would this approach work for other patients with obesity-related spinal epidural lipomatosis, or is this an exceptional case?
- How long must the weight loss be maintained to prevent recurrence of spinal fat accumulation?
- Could GLP-1-mediated weight loss be used as a first-line treatment before considering surgery for obesity-related spinal conditions?
Common questions
What is spinal epidural lipomatosis?
Can weight loss drugs replace spine surgery?
Read the original research
Complete radiologic and clinical reversal of lumbar spinal epidural lipomatosis via GLP-1 agonist.
Journal of surgical case reports, 2026(2), rjag052
Citation
Wurm, Lennard M; Koch, Peter; Ertel, Wolfgang; Laue, Dominik. (2026). Complete radiologic and clinical reversal of lumbar spinal epidural lipomatosis via GLP-1 agonist.. Journal of surgical case reports, 2026(2), rjag052. https://doi.org/10.1093/jscr/rjag052